|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
It was well documented that hypoxia-inducible factor-1α and fatty acid synthase were overexpressed in mammary gland carcinomas.
|
30950543 |
2019 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Fatty acid synthase (FASN) is overexpressed in most human carcinomas, including non-small cell lung cancer (NSCLC), and contributes to poor prognosis.
|
31122252 |
2019 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We analyzed the expression of FASN and Ki-67, by immunohistochemistry on 29 carcinomas ex-pleomorphic adenoma (CXPAs) and 25 pleomorphic adenomas (PAs).
|
30597641 |
2019 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Recent studies showed that Fatty Acid Synthase (FASN), a lipogenic enzyme overexpressed in several carcinomas, plays an important role in drug resistance.
|
30875891 |
2019 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
(-)-Epigallocatechin 3-gallate (EGCG) is a natural polyphenol from green tea with reported anticancer activity and capacity to inhibit the lipogenic enzyme fatty acid synthase (FASN), which is overexpressed in several human carcinomas.
|
29751678 |
2018 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of fatty acid synthase (FASN), the enzyme involved in the de novo synthesis of fatty acids, has been reported in several human carcinomas, including breast cancer, and has been related to poor prognosis.
|
23982110 |
2014 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Several studies have demonstrated that fatty acid synthase (FAS) levels (protein and mRNA) are over expressed in many carcinomas.
|
23142364 |
2012 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas.
|
22653145 |
2012 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Fatty acid synthase (FASN) expression and activity has emerged as a common phenotype in most human carcinomas, including breast cancer, and its expression is tightly linked to HER2 signaling pathways.
|
20973802 |
2010 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The enzyme fatty acid synthase (FASN) is highly expressed in many human carcinomas and its inhibition is cytotoxic to human cancer cells.
|
19189648 |
2009 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
FASN, a nearly-universal druggable target in many human carcinomas and their precursor lesions, offers new therapeutic opportunities for metabolically treating and preventing cancer.
|
17882277 |
2007 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Fatty acid synthase (FAS) has been shown previously to be highly expressed in breast and prostate carcinomas, but has low expression level in normal tissues.
|
17904792 |
2007 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
It now appears that human carcinomas and their pre-neoplastic lesions constitutively over express FAS and undergo significant endogenous fatty acid biosynthesis.
|
15577743 |
2005 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
H-FABP-positive and H-FABP-negative carcinomas were analyzed for their clinicopathologic characteristics and FAS status.
|
15459486 |
2004 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Both FAS mRNA and protein were significantly overexpressed in prostate carcinomas compared with the corresponding normal tissue.
|
12939396 |
2003 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of high levels of fatty acid synthase (FAS), an important enzyme in fatty acid synthesis, has been identified in a wide variety of human carcinomas.
|
9815604 |
1997 |